These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20047003)

  • 1. Drop-the-Losers Design: Binomial Case.
    Sill MW; Sampson AR
    Comput Stat Data Anal; 2009 Jan; 53(3):586-595. PubMed ID: 20047003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drop-the-losers design: normal case.
    Sampson AR; Sill MW
    Biom J; 2005 Jun; 47(3):257-68; discussion 269-81. PubMed ID: 16053251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.
    Neal D; Casella G; Yang MC; Wu SS
    Stat Med; 2011 Oct; 30(23):2804-14. PubMed ID: 21823142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.
    Jazić I; Liu X; Laird G
    J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parameter estimation following an adaptive treatment selection trial design.
    Luo X; Wu SS; Xiong J
    Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.
    Bowden J; Glimm E
    Biom J; 2014 Mar; 56(2):332-49. PubMed ID: 24353149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design.
    Karanevich A; Meier R; Graw S; McGlothlin A; Gajewski B
    Am Stat; 2019; 2019():. PubMed ID: 32981939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval estimation in multi-stage drop-the-losers designs.
    Lu X; He Y; Wu SS
    Stat Methods Med Res; 2018 Jan; 27(1):221-233. PubMed ID: 26980742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Adaptive Staggered Dose Design for a Normal Endpoint.
    Wu J; Menon S; Chang M
    J Biopharm Stat; 2015; 25(4):731-56. PubMed ID: 24904986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confidence intervals for confirmatory adaptive two-stage designs with treatment selection.
    Bebu I; Dragalin V; Luta G
    Biom J; 2013 May; 55(3):294-309. PubMed ID: 23553644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Samples of exact k-stage group sequential designs for Phase II and Pilot studies.
    Kepner JL; Chang MN
    Control Clin Trials; 2004 Jun; 25(3):326-33. PubMed ID: 15157732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A predictive probability interim design for phase II clinical trials with continuous endpoints.
    Liu M; Dressler EV
    Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients.
    Rai SN; Qian C; Pan J; Seth A; Srivastava DK; Bhatnagar A
    BMC Med Res Methodol; 2020 Aug; 20(1):220. PubMed ID: 32867708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.